🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06697418
Enrolling by invitation Observational

The Effect of Physical Activity Level Evaluated by Wrist-wearable Devices on Cardiovascular Disease Risk and Other Outcomes in Peritoneal Dialysis Patients

NCT06697418 · tracked via the Priya Life Science China tracker
Sponsor
Ruijin Hospital
Phase
Observational
Started
2024-10-01
Last updated
2024-11-20

Condition(s) studied

Peritoneal DialysisCardiovascular DiseasesMyocardial InfarctHeart FailureCognitive Disorders

Study summary

This study aims to explore how daily physical activity (PA) levels affect the heart health and cognitive function of patients on peritoneal dialysis (PD). Using a fitness tracker, the investigators will measure how much patients move during the day and see if lower activity levels are linked to a higher risk of heart disease or memory issues.

The study has two parts:

Part A: The investigators will evaluate 266 patients to understand their current PA levels and how these relate to heart health and cognitive function.

Part B: The investigators will follow the same patients over a year, measuring their activity at the beginning and after 12 months. The investigators will divide them into two groups-those who increase their PA and those whose PA decreases-and follow their heart health and memory function over two years.

The goal is to understand whether higher PA levels can reduce the risk of heart problems and memory issues in PD patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. 18 years old or above, under 75 years old 2. Receiving peritoneal dialysis treatment in Ruijin hospital for more than three months 3. Having the ability to walk independently 4. Willing to accept relevant training and sign informed consent Exclusion Criteria: 1. Unable or unwilling to provide written informed consent; 2. Unwilling to cooperate with regular follow-up or telephone follow-up; 3. Evidence of liver damage (ALT, AST≥ 2 times the upper limit of normal); 4. Patients with newly diagnosed malignant tumors in the past year or undergoing radiotherapy or chemotherapy; 5. NYHA class III or IV congestive heart failure, myocardial infarction, stable or unstable angina; 6. New-onset stroke (within the past 3 months, including cerebral hemorrhage and cerebral infarction); 7. Severe mental illness or a diagnosis of dementia.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Ruijin Hospital - Shanghai Jiaotong University School of Medicine Shanghai Shanghai Municipality

More Ruijin Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06697418 on ClinicalTrials.gov ↗ ← All trials in China